RE-109

Last updated
RE-109
RE-109.svg
Clinical data
Other namesPsilocin glutarate; Psilocin O-glutarate; RE109; RE-109; 4-Glutaryloxy-N,N-dimethyltryptamine; 4-HO-DMT O-glutarate; 4-GO-DMT; DMT-4-glutarate
Drug class Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Identifiers
  • 5-[[3-[2-(dimethylamino)ethyl]-1H-indol-4-yl]oxy]-5-oxopentanoic acid
PubChem CID
Chemical and physical data
Formula C17H22N2O4
Molar mass 318.373 g·mol−1
3D model (JSmol)
  • CN(C)CCC1=CNC2=C1C(=CC=C2)OC(=O)CCCC(=O)O
  • InChI=1S/C17H22N2O4/c1-19(2)10-9-12-11-18-13-5-3-6-14(17(12)13)23-16(22)8-4-7-15(20)21/h3,5-6,11,18H,4,7-10H2,1-2H3,(H,20,21)
  • Key:GIDBNBKWKCJUNZ-UHFFFAOYSA-N

O-Glutarylpsilocin (developmental code name RE109), also known as 4-glutaryloxy-N,N-dimethyltryptamine (4-HO-DMT O-glutarate) is a serotonergic psychedelic of the tryptamine family. [1] [2] It acts as a prodrug of psilocin (4-HO-DMT) similarly to other psilocin prodrugs like 4-AcO-DMT, 4-PrO-DMT, and psilocybin (4-PO-DMT). [1] [2] The drug is cleaved into psilocin by non-specific esterases. [1] [2] O-Glutarylpsilocin was first described in the scientific literature in 2024. [1] [2] It has been patented by Reunion Neuroscience. [2] A related drug, RE-104 (4-GO-DiPT), a prodrug of 4-HO-DiPT, is being developed for potential medical use. [1] [2]

Contents

See also

References

  1. 1 2 3 4 5 Bryson N, Alexander R, Asnis-Alibozek A, Ehlers MD (June 2024). "RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine". ACS Chem Neurosci. 15 (12): 2386–2395. doi:10.1021/acschemneuro.4c00058. PMC   11191588 . PMID   38758589.
  2. 1 2 3 4 5 6 "Improved pharmacokinetics of tryptamine prodrugs". Google Patents. 4 January 2024. Retrieved 1 April 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.